In silico approach towards H5N1 virus protein and transcriptomics-based medication by Tambunan, Usman Sumo Friend & Parikesit, Arli Aditya





Vol. 12(21), pp. 3110-3114, 22 May, 2013  
DOI: 10.5897/AJBX12.013 
ISSN 1684-5315 ©2013 Academic Journals  
http://www.academicjournals.org/AJB 









In silico approach towards H5N1 virus protein and 
transcriptomics-based medication 
 
Usman Sumo Friend Tambunan* and Arli Aditya Parikesit 
 
Department of Chemistry, Faculty of Mathematics and Science, University of Indonesia Depok 16424, Indonesia. 
 
Accepted 31 December, 2012 
 
H5N1 influenza A virus is a serious threat to human population. With a considerable mortality rate, 
strategies for coping with the infection are being developed. Our research group and some others 
investigated the potential therapeutic and preventive measures for tackling H5N1 infections. Protein-
based and transcriptomics analyses are getting more important in this field. The trends towards the 
integration of both protein-based and transcriptomics for H5N1 analysis are indeed feasible.  
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H5N1 influenza A virus, which is a highly pathogenic 
avian influenza (HPAI), has inflicted massive mortality in 
humans and poultry (Peiris et al., 2007). The whole Asia 
has been incurred by this virus. The H1N1 subtype 
(Spanish flu) caused much causality in 1918, with another 
occurrence again in Mexico (Swine flu) in 2009, causing 
many casualties as well (Asmara et al., 2005). The fatality 
of HPAI H5N1 threat must be further evaluated due to its 
economic impact. The complex nature of H5N1 infection 
has encouraged researchers to study its molecular 
mechanisms in order to develop the remedy (Peiris et al., 
2007). The antigenic drift in H5N1 that occurred due to its 
evolutionary course has enabled it to be transmitted from 
human to human, posing a terrible pandemic threat 
(Peiris et al., 2007).  
Out of the three strains of influenza viruses, A, B and C, 
type A is the most deadly of all, being responsible for 
epidemics that have been occurring every 10 to 40 years 
(Baigent and John, 2003). As a member of Orthomyxo-
viridae family, influenza virus A has eight segments of 
single stranded RNA: hemagglutinin (HA), neuraminidase 
(NA), polymerase basic 2 (PB2), polymerase basic 1 (PB1), 
polymerase acidic (PA), non-structural (NS), nucleopro-
tein (NP), and matrix (M). Till date, there are 16 detected 
types of HA and nine types of NA (Cox et al., 2005). 
The most important phase in the H5N1 infection is the 
viral attachment to sialic acid receptors in the surface of 
the host cell. The HA protein of avian influenza virus 
could only identify bird's [Neu5Ac (α2-3) Gal] receptors, 
and not that of humans [Neu5Ac (α2-6) Gal]. This re-
ceptor difference should disable the avian influenza virus 
from infect humans, but the possible antigenic drift/shift in 
HA has opened this possibility of global pandemic threat. 
It is suggested that mutation in other genes (that is, NA, 
PB1, PB2, NS, and M) could also boost the pathogenicity 
of H5N1 virus (Asmara et al., 2005). Low pathogenic form 
of mild avian influenza (LPAI) is also available besides 
HPAI; but the morbidity rate in HPAI could reach 100% 
(Asmara et al., 2005). 
Our research group has conducted research on HA, 
M1, NS1, NA, and M2 protein mutations of H5N1 (Tam-
bunan et al., 2012, 2010). However, we are aware of the 
protein-based and transcriptomic based research in other 
laboratories. The objective of this review was to compare 
both type of researches and determine the feasibility of 
transcriptomics and protein-based approach in coping
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Figure 1. Docking visualization of HA with sialic acid. A, Ile_225; B, Val_226; C, Lys_228; D, 




with H5N1 infections.  
 
 




We already conducted research on H5N1 computation 
that focused primarily on mutation studies. Our findings 
can be easily applied to a drug development study. 
The pathogenicity of influenza virus could be influenced 
by mutations with either antigenic shift or antigenic drift 
(Tambunan et al., 2010). HA, NA, and M2 are known to 
have important roles in the infection process of avian 
influenza virus. As usual, multiple alignment and phylo-
genetic tree construction were used for the in silico ana-
lyses. Both the cleavage and active sites underwent 
mutations of HA; with the active site also undergoing NA 
and M2 mutations. Hydrophilic to hydrophobic shift of the 
amino acid character influences the pathogenicity of the 
virus. Pro-P prediction was used for the mutation analysis 
result as well as 3D structure prediction, molecular doc-
king simulation and molecular dynamics simulation. R-X-
K/R-R pattern was obtained for H5N1 Indonesia and 
Hongkong due to the mutation analysis on HA cleavage 
site. Furin cleavage of HPAI H5N1's HA was shown by 
the pattern of Pro-P prediction. The strong binding of HA 
and NA H5N1 Indonesia towards human sialic acid 
receptor was analyzed by using molecular docking and 
molecular dynamics. However, amantadine and rimanta-
dine are resisted by the activity M2 protein of H5N1 virus. 
Figure 1 shows the visualization of HA with sialic acid. 
Overall, there is a strong relation between the patho-
genicity of H5N1 in Indonesia and the mutation of HA, NA 
and M2 based upon their binding with sialic acid recep-
tors (Tambunan et al., 2010).  
The latest research of Tambunan et al. (2012) was done 
through the observation of NS1 and M1 mutations in their 
entire region and the cleavage site of HA protein. With 
established methodology in Tambunan et al. (2010), the 
observation was followed by prediction of the pro-P (furin) 
HA specific cleavage, secondary structure, mutation 
(exposed/buried) prediction, epitope prediction, and 3-D 
structures prediction. RXK/RR conserved pattern of the 
mutation of HA cleavage site was found in Hong Kong 
H5N1, while the sequences of subtype H1N1, H1N2, and 
H3N2 lacked it. The cleavage of the HA of H5N1 is 
possible based on the detected pattern by the furin 
predictor. The position 53 of the mutation of NS1 control 
sequences was found in A/Indonesia/5/2005(H5N1), A/In-
donesia/CDC1032/2007(H5N1), A/HongKong/156/97
   






Figure 2. Superimposed RNA binding domain NS1. Figure taken from Usman et al. 




(H5N1), A/BrevigMission/1/18(H1N1), A/Mexico 
/InDRE4487/2009 (H1N1) with the subtypes H1N1, 
H1N2, and H3N2. However, these subspecies have no 
identical specific control mutation on the M1. There are 
248 changed positions in H1N1 and H3N2. The control 
sequences NS1 and M1 of H1N1, H1N2 and H3N2 sub-
types have similar inhibitory concentration at 50% (IC50) 
values below 50 nM based upon epitope prediction. 
However, the epitope recognition did not find any specific 
mutations. Secondary and tertiary structures of NS1 and 
M1 proteins were not significantly affected by the region-
specific mutations compared with the control sequences 
(Tambunan et al., 2012). Figure 2 shows the superimposed 
RNA Binding Domain of NS1. 
 
 
Discovery of other laboratories 
 
The nuclear magnetic resonance (NMR) spectroscopy 
has already successfully determined the 3D structures of 
the M2 proton channels for influenza A (Schnell et al., 
2008) and B (Wang et al., 2009) viruses. Synchronization 
of histidine protonation and opening of the channel gate 
have been emphasized by Pielak and Chou (2010). 
Moreover, destabilization of M2 helix-helix assembly by 
drug-resistant mutants could impair drug binding (Pielak 
et al., 2009). Allosteric mechanism of M2 NMR structure 
was supported by it being energetic, the channel-gating 
dynamic process, pK(a) shift, its impact on the channel 
and its consistency with previous functional studies (Du et 
al., 2009).  
Mutations of D44N, D44A and N44D on position 44, 
and mutations on positions 27 to 38 in M2 have been 
studied thoroughly for their functional features (Huang et 
al., 2008). On one hand, M2 ion-channel could be inhibi-
ted by adamantine, amantadine and rimantadine antiviral 
drugs which start to be ineffective due to mutations (De 
Clercq, 2006; De Jong et al., 2005). On the other hand, 
six analog inhibitors for H5N1 virus were proposed by Du 
et al. (2007). A series of docking studies have singled out 
nine analogs of AG7088, and zanamivir and oseltamivir 
have worse binding energy than the compound AG7088 
(Gong et al., 2009). The reduction of the high pathogen-
nicity of the virus could be fitted well if some mutations of 
H5N1 H5 cleavage sequence happened to disrupt the 
fitting into the furin. The sub-sites P(1), P(4) and P(6) 
from those findings could be focused on developing 
H5N1 drugs. Wang et al. (2007) conducted computational 
efforts to analyze BAE46950 sequence (homology model  





of H5N1-NA), with 21 sequences found from the data-
base of the 108 H5N1 NAs with over 95% sequence 
similarity with BAE46950. 
Moreover, the subtle mutated variations of the H5N1-
NA that change its complement interaction were found by 
Wei et al. (2006). The high resistance against existing NA 
inhibitors could be caused by those mutations. The for-
mation of stronger inhibition power than oseltamivir was 
possible by three lead compound derivatives of Wang et 
al. (2010). Henceforth, development of new and more 
powerful drugs for treating influenza could be pursued by 
the utilization of those candidates. These advancements 
in the field of protein-based computation could possibly 
lead to the development of new therapeutic and preven-
tive agents.  
 
 
TRANSCRIPTOMICS STUDIES OF H5N1 VIRUS 
 
According to the study of Koparde and Singh (2011), the 
silencing of the pathogenic gene products associated with 
viral infections could be utilized by RNA interference 
(RNAi) mediated by microRNA (miRNA). Koparde and 
Singh (2011) have reviewed the role of miRNA in its 
pathophysiology and the computational prediction of 
miRNA as antiviral therapeutics. The highly variable na-
ture of influenza antigenic proteins could eventually break 
down the efficacy of the conventional influenza drugs. 
The fund-saving nature of in silico prediction of sequence 
specific therapeutics would be helpful in determining the 
miRNA target prediction platforms, which are very differ-
ent in their specificity and sensitivity in prediction. 
Moreover, Koparde and Singh (2010) also propose a 
bioinformatics pipeline to convey prediction of microRNAs 
that posed activity against non-structural protein 1 of 
H5N1 and segment 8 of H1N1 virus. They found several 
potential sequence specific miRNA therapeutic agents 
against NS1 protein of H5N1 virus. Those are hsa-miR-
138, hsa-miR-525-5p and hsa-miR-124. The possible anti- 
influenza agents were extracted from the different H1N1 
segment 8 genomes that resulted from the predic-tion of 
miRNAs.  
The regulatory processes of host cell, stress related 
pathways including mitogen-activated protein kinase 
(MAPK) and mammalian target of rapamycin (mTOR) path 
ways are predicted to be regulated by the micro RNAs. 
Those predicted miRNAs are also expected to be involved 
in pathways related to cancer (Koparde and Singh, 2010). 
ElHefnawi et al. (2011) designed optimal small inter-
fering RNA molecules (siRNAs) for targeting all diverse 
influenza A viral strains. The analysis performed on possi-
ble influenza-targeting siRNAs resulted from the rational 
integration of the highly efficient design in the pipeline.  
The siRNA that has the ability to target highly con-
served, an accessible and biologically significant region 
has been selected in this analysis, it only requires mini-
mal dosage and side effects. The design of more than 
6000 possible siRNA was devised. The elimination of those 




with off-targets in the human genome and those with 
undesirable properties and selection of siRNA tar-geting 
highly probable single-stranded regions were done as 
further filtration of siRNAs. The selection conserved and 
biologically functional short motifs were the final stage of 
the optimization of the properties of siRNA. The fertility of 
this methodology was shown by validation of a predicted 
active (sh114) and a predicted inactive (sh113) (that was 
filtered out in Stage 8) silencer of the NS1 gene that 
eventually showed significant inhibition of the NS1 gene 
for sh114, with negligible decrease for sh113 which failed 
target accessibility (ElHefnawi et al., 2011). These findings 
in the field of transcriptomics are promising for utilization 
as drug or vaccines. 
 
 
FUTURE PROSPECTS: INTEGRATION OF PROTEIN-
BASED AND TRANSCRIPTOMICS 
 
Advanced researches of protein informatics have already 
been intersected with the realm of transcriptomics. Some 
research groups have shown that the protein repertoire of 
the organism is indeed exposing its transcriptomics pro-
perties. Parikesit et al. (2011) have already worked on 
domain co-occurrences and Moore et al. (2012), on domain 
loss/gain. Parikesit et al. (2011) found that transcription 
factor domains are having tendency to avoid each other 
on multicellular organism, while co-occurrence happens 
on the simple/basal organism. Moore et al. (2012) also 
found that optomotor domain, which co-occurs with 
members of the T-box family, an ancient transcriptional 
regulator, is emerging in Drosophila. This protein-based 
discovery has exposed the potential transcriptomic 
expression of the living entities. They have eventually 
annotated an important protein repertoire with roles in 
transcription factors, which are the cardinal requirements 
for transcriptomics expression. The research on trans-
cription factor domain repertoire is eventually leading to 
more emphasis on its interrelationship with transcriptomic 
that would be useful on virology informatics. It could be 
inferred that extensive protein-based studies will lead to 
the deeper understanding of transcriptomics.  
There are some research groups who have already 
realized the potential of transcriptomics and proteomics 
integration. Com et al. (2011) successfully provided com-
prehensive evaluation on integration of transcriptomics 
and proteomics on gentamicin nephrotoxicity in rats. 
Meanwhile, Piruzian et al. (2010) have proposed a pipe-
line for network analysis towards integration of transcrip-
tomics and proteomics in psoriasis. Their researches are 
the important motivation for the creation of a proteomic 
and transcriptomic therapeutic library. 
Within our future work, we plan to apply the integration 
of protein-based and transcriptomics data for developing 
a comprehensive H5N1 drug design library. We will work 
more on transcriptomics research as well, since we 
already possess the necessary skill for it. The research of 
Hofacker et al. (1998, 1999, 2002) have shown  that transcript- 
   




tomic expression of viral genome could be annotated. 
Moreover, having a more complete viral protein annota-
tion, using gene prediction package would be a feasible 
option as well (Parikesit et al., 2011). It would be interes-
ting to exploit more viral bioinformatics research using 
both approaches for producing more biological conclusion 
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